AzTrials
AzTrials

Pregnancy TestsNCT03975933

Pregnancy Testing in Northern Uganda

A study testing Pregnancy test at Baseline, Free pregnancy test for the future use and Pregnancy test for the future use with randomzied price in people with Pregnancy Tests, run by University of Illinois at Urbana-Champaign at 1 site in Uganda.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Given the high rate of delayed adoption of antenatal care (ANC), and high rates of unintended pregnancy and unsafe abortion in Uganda, research on the period of time before confirmation of pregnancy is critical to understand underlying beliefs that guide behaviors ultimately important for maternal and neonatal health… Read more about this study

Who is it for?
Ages 18 to 35 years, women onlyHealthy volunteers can take part
Conditions the study is for
Pregnancy Tests
What is being tested?
Pregnancy test at Baseline, Free pregnancy test for the future use and Pregnancy test for the future use with randomzied price
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,033 participants
Where
1 siteUganda
Study dates
14 May 2019to 31 Dec 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Between the ages of 18-35
  • Live in the catchment area
  • Sexually Active

Who cannot join

  • Currently, pregnant women or women who recently gave birth (within 6 weeks of interview)
  • Already using long-term family planning methods (IUD, implant, sterilization)
  • End Survey if
  • Women in menopause
  • Women with sterilization
  • Women with husband/partner with sterilization
Show all 9Show fewer
  • Women with long-term family planning methods (IUD and implant)
  • Women who do not understand what menstrual period is
  • Women who is currently pregnant or who recently gave a birth (within 6 weeks of interview)

Trial locations and contacts

1 site in 1 country.

Uganda1 site
  • Ichuli Institute

    Kampala

Other trials in Uganda

About this study

Given the high rate of delayed adoption of antenatal care (ANC), and high rates of unintended pregnancy and unsafe abortion in Uganda, research on the period of time before confirmation of pregnancy is critical to understand underlying beliefs that guide behaviors ultimately important for maternal and neonatal health (UDHS, 2011; Hussain, 2013).

Home pregnancy tests - which now cost less than 10 cents each - have the potential to facilitate FP uptake and significantly improve reproductive, maternal and child health outcomes in sub-Saharan Africa, including Uganda. These tests are easy to administer, disposable, inexpensive, and have a low false positive rate. Yet, for women living in rural areas in sub-Saharan countries, these tests are typically unavailable outside of health centers or they are prohibitively expensive.

Read more

This study will investigate women's underlying beliefs about pregnancy status and examine how providing access to home-based pregnancy tests - thus facilitating earlier resolution of uncertainty of pregnancy status - influences such beliefs and decisions to take up family planning (FP).

The results will inform the design of a larger study in the future.

Read the detailed description

Given the high rate of delayed adoption of antenatal care (ANC), and high rates of unintended pregnancy and unsafe abortion in Uganda, research on the period of time before confirmation of pregnancy is critical to understand underlying beliefs that guide behaviors ultimately important for maternal and neonatal health (UDHS, 2011; Hussain, 2013).

Unmet demand for contraceptives remains high in sub-Saharan Africa, with 25% of married women reporting wanting to avoid pregnancy but not currently using modern contraceptives (Clifton and Kaneda, 2013). One factor contributing to unmet demand is that women are refused access to hormonal contraceptives in some settings, because FP providers cannot rule out pregnancy if the woman is not menstruating at the time of her visit (Campbell et al., 2006; Shelton et al., 1992; Stanback et al., 1997). While the current standard is for health providers to use a simple six-question checklist to rule out pregnancy, the checklist has a false positive rate ranging from 11% to 64% (Tepper et al. 2013) and health workers often end up not trusting it (Comfort et al., 2016; Hoke et al., 2012). Pregnancy tests can give non-menstruating women the ability to confirm they are not pregnant and access hormonal contraceptive methods when they may otherwise be denied (Stanback et al., 2013). Greater access to pregnancy tests may also motivate women who are uncertain about their pregnancy status to adopt FP methods if they receive a negative test result and do not wish to have additional children. The administration of a home pregnancy test by a FP provider, including community health workers, can also serve as an opportunity for FP counseling which may further increase uptake.

Confirmation of negative pregnancy status can also reduce psychological anxiety, especially for women who may wish to delay or avoid becoming pregnant. Among women who may be using different forms of contraceptives, confirmation of negative pregnancy could provide proof of the methods' effectiveness thereby encouraging these women to continue use. Almost half of women in Uganda who adopt a contraceptive method discontinue use within 12 months and about 13% discontinue use of short-acting hormonal contraceptives because of method failure ((UBOS) and International 2012). Especially among women using these particular methods, confirming their negative pregnancy status could encourage them to continue use. For women with partners who want to delay or avoid pregnancy, confirming negative pregnancy status could reduce domestic violence and reduce marital distress. In Uganda, almost 60% of women have experienced physical violence in their lifetime, and 60% of these women report that perpetrator was their current spouse ((UBOS) and International 2012). In addition, among Ugandan women who have ever been pregnant, 16% report having experienced physical violence during pregnancy; the likelihood of violence during pregnancy is higher for women who have five or more children, lower education, or lower income ((UBOS) and International 2012). Confirmation of negative pregnancy could also aid with household decision-making and planning; for example, women who confirm they are not pregnant could make greater investment (financial, time, physical) in their children.

Although coverage for at least one ANC visit is high in most developing countries, this is not predictive of coverage for at least four visits - the previous number of recommended visit by the World Health Organization (AbouZahr and Wardlaw, 2001) and is far from reaching the most recent WHO recommendation of at least 8 visits during a pregnancy (WHO 2016). According to the 2011 Uganda Demographic and Health Survey, 95% of women receive ANC from a skilled provider. However, only 48% attend four or more visits, and the median gestational age at the first visit is 5.1 months - well into the second trimester - even though the WHO recommends initiating ANC as early as possible (UDHS, 2011). There is some existing evidence suggesting that women wait to seek ANC because of uncertainty about their pregnancy status (Myer and Harrison, 2003).

In addition, earlier recognition of a pregnancy could allow women to plan for unwanted pregnancies. For pregnancies that are carried to term, earlier recognition would allow women to adopt healthy prenatal behaviors earlier (such as avoiding alcohol consumption and smoking, taking prenatal vitamins, and using antimalarial bednets). Women would be better able to plan for the delivery, including saving for delivery-related costs, such as transportation, provider fees, and facility fees and planning for the location of the delivery and attendance at delivery. It would also allow women to adopt effective malaria prevention behaviors; while the WHO recommends that pregnant women receive intermittent preventive treatment for malaria as soon as possible in the 2nd trimester, pregnant women should be using anti-malarial bednets during the 1st trimester (when iPTP is contra-indicated) to protect against malaria infection, which can result in maternal and fetal anemia, placental parasitaemia, low birth weight, and neonatal mortality (WHO 2012).

Home pregnancy tests - which now cost less than 10 cents each - have the potential to facilitate FP uptake and significantly improve reproductive, maternal and child health outcomes in sub-Saharan Africa, including Uganda. These tests are easy to administer, disposable, inexpensive, and have a low false positive rate. Yet, for women living in rural areas in sub-Saharan countries, these tests are typically unavailable outside of health centers or they are prohibitively expensive. This study will investigate women's underlying beliefs about pregnancy status and examine how providing access to home-based pregnancy tests - thus facilitating earlier resolution of uncertainty of pregnancy status - influences such beliefs and decisions to take up family planning (FP) or seek appropriate pregnancy services.

This protocol outlines our proposed study. The results will inform the design of a larger study.

  1. Objectives

The main objectives of this study are to understand the impact of increasing women's access to home pregnancy tests on reproductive health care seeking. In this study we focus on non-pregnant women and subsequent effects of access to pregnancy tests. Specifically, the main research questions of the proposed study are:

  1. Beliefs: How do women form their beliefs about their pregnancy status, risk of pregnancy and how do these beliefs correlate with behaviors related to contraceptive adoption among non-pregnant women?
  2. Effects of access to pregnancy tests: What are the effects of resolving uncertainty through home pregnancy tests on beliefs and reproductive behaviors including FP uptake, psychological well-being, and contraceptive continuation)?
  3. Demand/Value of pregnancy tests: What is take-up of free pregnancy tests and if the test is distributed for free, at what point in time in the month (in relationship to their menstrual cycle or sexual behavior) do women most value using it if they are distributed for free? Does willingness to pay for these tests vary by prior experience with pregnancy tests and key characteristics such as age and number of previous pregnancies?

We hypothesize that providing access to pregnancy tests could influence reproductive behaviors in the following ways:

Hypothesis 1: For women who test negative, confirmation of negative pregnancy status using home pregnancy tests will facilitate adoption of modern contraceptives to prevent unintended pregnancies and reduce anxiety.

Hypothesis 2: Women who are most uncertain of their pregnancy status (correlated with beliefs and sexual behavior) will have a higher value of the pregnancy test (more willing to adopt or higher willingness to pay).

Conditions
Pregnancy Tests
Being tested
Pregnancy test at Baseline, Free pregnancy test for the future use, Pregnancy test for the future use with randomzied price
Keywords
Reproductive Health, Family Planning, Randomization Trial, Uganda

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Pregnancy test at BaselineDiagnostic test

    Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.

  • Free pregnancy test for the future useDiagnostic test

    We will provide a free pregnancy test in for the future use.

  • Pregnancy test for the future use with randomzied priceDiagnostic test

    We will provide an opportunity to buy a pregnancy test for the future use with randomized price.

Study groups in NCT03975933
Study groupRoleWhat they receive
Free pregnancy tests at baseline but not for the futureExperimentalWe offer free pregnancy test service at baseline but the respondents do not have an opportunity to receive or buy a pregnancy test.
Receives: Diagnostic Test: Pregnancy test at Baseline
Free pregnancy tests at baseline and for the futureExperimentalWe offer free pregnancy test service at baseline and a free pregnancy test for future use.
Receives: Diagnostic Test: Pregnancy test at Baseline; Diagnostic Test: Free pregnancy test for the future use
Free pregnancy tests at baseline and future use (random price)ExperimentalWe offer free pregnancy test service at baseline and the respondents have an opportunity to buy a pregnancy test.
Receives: Diagnostic Test: Pregnancy test at Baseline; Diagnostic Test: Pregnancy test for the future use with randomzied price
Control GroupNo interventionControl group. No intervention is implemented.
Pregnancy test for the future useExperimentalNo free pregnancy tests at baseline, but receive a free pregnancy test for the future.
Receives: Diagnostic Test: Free pregnancy test for the future use
Pregnancy test for the future with random priceExperimentalNo free pregnancy tests at baseline, but receive an opportunity to buy a pregnancy test for the future (ranodmized price).
Receives: Diagnostic Test: Pregnancy test for the future use with randomzied price

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Binary measures for the family planning take up

    Use of short-term modern family planning short-acting reversible methods. We will measure take up as binary variables.

    Measured: 1 month after baseline

  2. Binary measure of purchase of pregnancy test kit by price

    Binary measures for the purchase of pregnancy test kit after baseline. Demand for pregnancy test kit is computed by Take it or leave it (TIOLI) method.

    Measured: 1 month after baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Jun 2019
  2. Study start14 May 2019
  3. Primary completion10 Sep 2019
  4. Study completion31 Dec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,033 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03975933
Sponsor's protocol ID
UIUC_PT
Status last verified
Jan 2019
First submitted
30 Jul 2018
Last updated
13 Nov 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Kamei A, Sato R, Thornton R. Factors associated with knowledge and use of home pregnancy test kits in Uganda. PLOS Glob Public Health. 2023 Jul 13;3(7):e0002165. doi: 10.1371/journal.pgph.0002165. eCollection 2023.

    PubMed 37440465
  • Kamei A, Sato R, Thornton R. Effect of pregnancy tests on demand for family planning: evidence from a randomized controlled trial in Uganda. Reprod Health. 2021 Nov 15;18(1):231. doi: 10.1186/s12978-021-01279-5.

    PubMed 34781969

Questions about this trial

What is this clinical trial studying?

A study testing Pregnancy test at Baseline, Free pregnancy test for the future use and Pregnancy test for the future use with randomzied price in people with Pregnancy Tests, run by University of Illinois at Urbana-Champaign at 1 site in Uganda.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 13 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Binary measures for the family planning take up (time frame: 1 month after baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03975933, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Nov 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in